Prognosis in HIV-infected patients with non-small cell lung cancer

British Journal of Cancer

Volumn 109, Issue 7, 2013, Pages 1974-1980

  Sigel, K ^a   Crothers, K ^b   Dubrow, R ^c   Krauskopf, K ^a   Jao, J ^a   Sigel, C ^d   Moskowitz, A ^a   Wisnivesky, J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

competing risks; HIV; immunosuppression; lung cancer epidemiology; lung cancer prognosis; non small cell lung cancer

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HEALTH STATUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HIV INFECTIONS; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SEER PROGRAM; SURVIVAL RATE; UNITED STATES;

EID: 84885173039     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.545     Document Type: Article

References (37)

1. Allignol A, Latouche A, Yan J, Fine J (2011) A regression model for the conditional probability of a competing event: application to monoclonal gammopathy of unknown significance. Appl Stat 60: 135-14.
2. Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL (2002) Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care 40(8 Suppl): 19-25.
3. Biggar RJ, Engels EA, Ly S, Kahn A, Schymura MJ, Sackoff J, Virgo P, Pfeiffer RM (2005) Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr 39: 293-299.
4. Bourcier V, Winnock M, Ait Ahmed M, Sogni P, Pambrun E, Poizot-Martin I, Chaffaut C, Chevret S, Trinchet JC, Salmon D (2012) Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir). Clin Res Hepatol Gastroenterol 36: 214-221.
5. Buell JF, Papaconstantinou HT, Skalow B, Hanaway MJ, Alloway RR, Woodle ES (2005) De novo colorectal cancer: five-year survival is markedly lower in transplant recipients compared with the general population. Transplant Proc 37: 960-961.
6. Centers for Disease Control (2012) HIV in the United States: At A Glance. United States Centers for Disease Control and Prevention: Atlanta, Georgia, USA. Available at: http://www.cdc.gov/hiv/statistics/basics/ataglance.html.
7. Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45: 613-619.
8. Doria-Rose VP, Marcus PM (2009) Death certificates provide an adequate source of cause of death information when evaluating lung cancer mortality: an example from the Mayo Lung Project. Lung Cancer 63: 295-300.
9. Fasciano NJ, Cherlow AL, Turner BJ, Thornton CV (1998) Profile of Medicare beneficiaries with AIDS: application of an AIDS casefinding algorithm. Health Care Financ Rev 19: 19-38.
10. Genova C, Rijavec E, Barletta G, Sini C, Dal Bello MG, Truini M, Murolo C, Pronzato P, Grossi F (2012) Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer. Expert Opin Biol Ther 12: 939-948.
11. Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D (2009) Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 10: 1152-1159.
12. Hakimian R, Fang H, Thomas L, Edelman MJ (2007) Lung cancer in HIV-infected patients in the era of highly active antiretroviral therapy. J Thorac Oncol 2: 268-272.
13. Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, Itoh T, Ohbuchi T, Kondo S, Katoh H (2006) Concurrent infiltration by CD8\+ T cells and CD4\+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 94: 275-280.
14. Kirk GD, Merlo CA (2011) HIV infection in the etiology of lung cancer: confounding, causality, and consequences. Proc Am Thorac Soc 8: 326-332.
15. Klabunde CN, Harlan LC, Warren JL (2006) Data sources for measuring comorbidity: a comparison of hospital records and medicare claims for cancer patients. Med Care 44: 921-928.
16. Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F, Francioli P, D'Arminio Monforte A, Fox Z, Lundgren JD (2002) Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 16: 1663-1671.
17. NCCN (2011) Clinical practice guidelines in oncology: non-small cell lung cancer. National Comprehensive Cancer Network.
18. NCI.gov (2013) Cause-specific Death Classification.
19. O'Callaghan DS, O'Donnell D, O'Connell F, O'Byrne KJ (2010) The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol 5: 2024-2036.
20. Pepe MS, Mori M (1993) Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 12: 737-751.
21. Pintilie M (2006) Competing Risks: A Practical Perspective. Wiley and Sons: West Sussex, England, USA.
22. Poluri A, Shah KG, Carew JF, Shaha AR, Har-El G, Lucente FE, Singh B (2002) Hodgkin's disease of the head and neck in human immunodeficiency virus-infected patients. Am J Otolaryngol 23: 12-16.
23. Rengan R, Mitra N, Liao K, Armstrong K, Vachani A (2012) Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study. Lancet Oncol 13: 1203-1209.
24. Rodrigues LK, Klencke BJ, Vin-Christian K, Berger TG, Crawford RI, Miller 3rd JR, Ferreira CM, Nosrati M, Kashani-Sabet M (2002) Altered clinical course of malignant melanoma in HIV-positive patients. Arch Dermatol 138: 765-770.
25. Shiels MS, Cole SR, Chmiel JS, Margolick J, Martinson J, Zhang ZF, Jacobson LP (2010) A comparison of ad hoc methods to account for non-cancer AIDS and deaths as competing risks when estimating the effect of HAART on incident cancer AIDS among HIV-infected men. J Clin Epidemiol 63: 459-467.
26. Shiels MS, Cole SR, Kirk GD, Poole C (2009) A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 52: 611-622.
27. Shrestha S, Johnson D, Porter D, Reid E, Palchinsky J, Napravnik S, Mathews W, Eron J, Saag M (2012) HIV prevalence among cancer patients in 3 urban oncology clinics. Conference on Retroviruses and Opportunistic Infections. ,Vol. Abstract #904. Seattle, WA, USA.
28. Sigel K, Wisnivesky J, Gordon K, Dubrow R, Justice A, Brown ST, Goulet J, Butt AA, Crystal S, Rimland D, Rodriguez-Barradas M, Gibert C, Park L, Crothers K (2012) HIV as an independent risk factor for incident lung cancer. AIDS 26: 1017-1025.
29. Suneja G, Shiels MS, Melville SK, Williams MA, Rengan R, Engels EA (2013) Disparities in the treatment and outcomes of lung cancer among HIV-infected people in Texas. AIDS 27: 459-468.
30. Tirelli U, Spina M, Sandri S, Serraino D, Gobitti C, Fasan M, Sinicco A, Garavelli P, Ridolfo AL, Vaccher E (2000) Lung carcinoma in 36 patients with human immunodeficiency virus infection. The Italian Cooperative Group on AIDS and Tumors. Cancer 88: 563-569.
31. Unites States Social Security Administration (2013) Disability Evaluation Under Social Security.
32. Virnig BA, Warren JL, Cooper GS, Klabunde CN, Schussler N, Freeman J (2002) Studying radiation therapy using SEER-Medicare-linked data. Med Care 40(8 suppl): 49-54.
33. Warren JL, Harlan LC, Fahey A, Virnig BA, Freeman JL, Klabunde CN, Cooper GS, Knopf KB (2002) Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 40: 55-61.
34. Wisnivesky JP, Smith CB, Packer S, Strauss GM, Lurslurchachai L, Federman A, Halm EA (2011) Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer: observational cohort study. BMJ 343: d4013.
35. Wistuba II, Behrens C, Milchgrub S, Virmani AK, Jagirdar J, Thomas B, Ioachim HL, Litzky LA, Brambilla EM, Minna JD, Gazdar AF (1998) Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects. JAMA 279: 1554-1559.
36. Zhou X, Kemp BL, Khuri FR, Liu D, Lee JJ, Wu W, Hong WK, Mao L (2000) Prognostic implication of microsatellite alteration profiles in early-stage non-small cell lung cancer. Clin Cancer Res 6: 559-565.
37. Zwahlen M, Harris R, May M, Hogg R, Costagliola D, de Wolf F, Gill J, Fatkenheuer G, Lewden C, Saag M, Staszewski S, d'Arminio Monforte A, Casabona J, Lampe F, Justice A, von Wyl V, Egger M (2009) Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol 38: 1624-1633.